Cigna: A Healthy Pick, Deal or No Deal
February 10, 2017 at 10:37 AM EST
Frank Morgan , the analyst at RBC Capital Markets sees 19% upside for Cigna ( CI ) despite a federal court ruling earlier this week banning its big merger with Anthem ( ANTM ). He upgraded the stock to an outperform with a $172 price target, arguing that the insurer will fare just fine on its own, citing several tailwinds that “should help drive the industry's best earnings growth in FY17,” augmented by significant capital deployment.